2. Search Result
Search Result
Results for "

pharmacodynamic inhibition

" in MedChemExpress (MCE) Product Catalog:

10

Inhibitors & Agonists

1

Natural
Products

4

Isotope-Labeled Compounds

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-162255
    CDK2-IN-23

    		CDK Cancer
    CDK2-IN-23 (Compound 17) is a kinase selective and highly potent CDK2 inhibitor (IC50 = 0.29 nM). CDK2-IN-23 shows the pharmacodynamic inhibition of CDK2 in CCNE1-amplified mouse models. CDK2-IN-23 can be used for the research of cancer .
    CDK2-IN-23
  • HY-B0377
    Famotidine
    5+ Cited Publications

    MK-208

    		 Histamine Receptor Cardiovascular Disease Metabolic Disease Endocrinology Cancer
    Famotidine (MK-208) is a competitive histamine H2-receptor antagonist. Its main pharmacodynamic effect is the inhibition of gastric secretion.
    Famotidine
  • HY-B0377R
    Famotidine (Standard)

    MK-208 (Standard)

    		 Reference Standards Histamine Receptor Metabolic Disease Endocrinology Cancer
    Famotidine (Standard) is the analytical standard of Famotidine. This product is intended for research and analytical applications. Famotidine (MK-208) is a competitive histamine H2-receptor antagonist. Its main pharmacodynamic effect is the inhibition of gastric secretion.
    Famotidine (Standard)
  • HY-B0377S1
    Famotidine-13C

    MK-208-13C

    		 Isotope-Labeled Compounds Histamine Receptor Cardiovascular Disease Metabolic Disease Endocrinology Cancer
    Famotidine- 13C (MK-208- 13C) is 13C labeled Famotidine. Famotidine (MK-208) is a competitive histamine H2-receptor antagonist. Its main pharmacodynamic effect is the inhibition of gastric secretion.
    Famotidine-13C
  • HY-B0377S
    Famotidine-13C,d3

    		Isotope-Labeled Compounds Histamine Receptor Metabolic Disease Endocrinology
    Famotidine- 13C,d3 is the 13C- and deuterium labeled Famotidine. Famotidine (MK-208) is a competitive histamine H2-receptor antagonist. Its main pharmacodynamic effect is the inhibition of gastric secretion.
    Famotidine-13C,d3
  • HY-W707517
    Famotidine-d4

    MK-208-d4

    		 Isotope-Labeled Compounds Histamine Receptor Cardiovascular Disease Metabolic Disease Endocrinology Cancer
    Famotidine-d4 (MK-208-d4) is deuterium labeled Famotidine. Famotidine (MK-208) is a competitive histamine H2-receptor antagonist. Its main pharmacodynamic effect is the inhibition of gastric secretion .
    Famotidine-d4
  • HY-W777002
    Famotidine-13C3

    MK-208-13C3

    		 Isotope-Labeled Compounds Histamine Receptor Cardiovascular Disease Metabolic Disease Endocrinology Cancer
    Famotidine- 13C3 (MK-208- 13C3) is the 13C-labeled Famotidine (HY-B0377). Famotidine (MK-208) is a competitive histamine H2-receptor antagonist. Its main pharmacodynamic effect is the inhibition of gastric secretion.
    Famotidine-13C3
  • HY-N8265
    Abyssinone V

    		HSV DNA/RNA Synthesis ATP Synthase Infection
    Abyssinone V is a prenylated flavonoid with predicted anti-viral activity. Abyssinone V can be isolated from the stem bark of Erythrina melanacantha. Abyssinone V possesses good pharmacodynamics properties. Abyssinone V is predicted to be antivirals including anti-herpes (HSV) agent, with mechanisms comprising inhibition of polymerase, ATPase and membrane integrity .
    Abyssinone V
  • HY-19517
    R1663

    		Endogenous Metabolite Cardiovascular Disease
    R1663 is a factor Xa inhibitor with anticoagulant activity. R1663 does not affect bleeding time. The pharmacodynamic effects (such as inhibition of thrombin generation) and plasma concentrations of R1663 are dose-dependent. R1663 prolongs clotting time in a concentration-dependent manner and inhibits the peak height of thrombin generation and endogenous thrombin potential .
    R1663
  • HY-117087
    K103

    		Phosphatase Cancer
    K103 is an inhibitor discovered from the screen that is an analog of the serotonin antagonist benzazocine. K103 exhibited inhibition of SHIP homologues, labelling it a pan-SHIP1/2 inhibitor, but the molecule had no effect on another 5' inositol phosphatase, OCRL. In line with the "two PIPs hypothesis", the molecule exhibited significant anti-tumour effects against a variety of cell lines, particularly breast cancer cells. Additional studies with K103 revealed that inhibition of SHIP1/2 in multiple myeloma cells resulted in G2/M cell cycle arrest followed by extensive apoptosis via activation of the caspase cascade. K103 fits the commonly used small molecule agent property profile, but while this work was being conducted, it was discovered that K103 caused psychoactive effects in mice, which limited the utility of the molecule in vivo. Therefore, certain synthetic studies were conducted on this tryptamine to identify the features that needed to be present in the molecule to maintain pan-SHIP1/2 inhibition in order to design an inhibitor with favourable pharmacodynamic properties and an improved side effect profile.
    K103

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: